Introduction
Bortezomib (Velcade, Millennium Pharmaceuticals (Cambridge, MA, USA)) is an irreversible inhibitor of proteasome function that has shown clinical efficacy in patients with multiple myeloma and other neoplasms.
1,2 Bortezomib induces apoptosis of a variety of proliferating tumor cells both in vitro and in vivo. 3, 4 The mechanism(s) linking proteasome inhibition to apoptosis is incompletely understood, although it appears to include inhibition of nuclear factor-kB 5 and of mitogen-activated protein kinases, 6 as well as downregulation of the intracellular levels of antiapoptotic proteins. 7 Proteasome inhibition may affect both innate and adaptive immunity. Bortezomib induces apoptosis of activated antigen-specific, but not resting, T lymphocytes 8 in vitro, and inhibits T-cell function in vivo in GVHD models. 9, 10 There is extensive evidence that Bortezomib induces the apoptosis of in vitro monocyte-derived immature and mature DCs. [11] [12] [13] [14] However, it is not known whether Bortezomib induces the apoptosis of 'native' DC circulating in the peripheral blood, although it may alter the function of circulating myeloid DC ex vivo. 15 Moreover, the effects of Bortezomib on monocytes have not been thoroughly investigated. Besides being a major source of DC both in vitro and in vivo, monocytes play a role in a variety of chronic inflammatory disorders, including Systemic Lupus Erythematosus 16 and Systemic Sclerosis. 17 GVHD, in particular, requires alloantigen presentation by recipient APC in animal models, 18 and appears to correlate with recipient monocyte numbers in human transplantation. 19 In this study, we show that Bortezomib induces selective apoptosis of monocytes, following short term in vitro culture, suggesting its potential ability to prevent GVHD when administered in vivo.
Materials and methods
Bortezomib (Velcade) was purchased from Janssen Cilag and stored at À80 1C after being dissolved in DMSO until use. GM-CSF (Mielogen, Schering-Plough, Milano, Italy) and IL-4 (Endogen, Rockford, IL, USA) were used at 1.000 U/ml and 800 U/ml, respectively. Lipopolysaccharide and PHA were both purchased from Sigma (St Louis, MO, USA) and used at a concentration of 1 and 10 mg/ml, respectively. Unconjugated anti-CD3 MoAb was purchased from BD-Pharmingen (Milano, Italy) and used at 1 mg/ml. IL-3 was purchased from Biodesign International (Memphis, TN, USA) and used at 50 ng/ml. All reagents except Bortezomib were dissolved in PBS.
Cell isolation and culture
All cell subsets except CD34 þ cells were purified from buffy coats from healthy blood donors provided by the blood bank at the local hospital. CD34 þ cells were purified from aliquots of PBSC products (maximum 5 Â 10 8 cells) obtained from healthy G-CSF-primed PBSC donors following written informed consent. Mononuclear cells (MNCs) were enriched by density gradient centrifugation over Ficoll-Hypaque (Nycomed Pharma, Oslo, Norway). Monocytes, B lymphocytes and CD34 þ cells were isolated by immunomagnetic bead-based positive selection (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Briefly, MNCs were incubated for 15 min at 4 1C with either anti-CD14 or anti-CD19 MoAb conjugated to magnetic beads, and then positive cells were selected by running them through LD columns (Miltenyi Biotech) placed in a magnetic field. Selection of CD34 þ cells was performed by using the CD34 þ selection kit, as described. 20 Cell purity was assessed by flow cytometry and was consistently 495%. T lymphocytes were enriched to 480% by negative selection through adherence of MNC to plastic dishes for 1 h at 37 1C.
Cell cultures were performed in RPMI 1640 medium containing 25 mM HEPES, 1 U/ml penicillin, 1 mg/ml streptomycin, 100 mM L-glutamine, 50 mM 6-mercaptoethanol, 1% non-essential amino acids (all from Invitrogen, Grand Island, NY, USA) and 10% FCS that had been inactivated at 56 1C for 30 min, herein defined as complete medium, at 37 1C, 5% CO 2 , for the indicated time. GM-CSF was added to cultures of purified monocytes to prevent spontaneous apoptosis (36 ± 13%, n ¼ 5, data not shown), 21 whereas IL-3 was added to cultures of purified CD34 þ progenitor cells to maintain their viability. 22 Anti-CD3 or PHA were added to cultures of purified T lymphocytes, when indicated, to induce proliferation. Bortezomib was added at the start of the culture at the indicated concentrations, ranging from 0.1 to 100 ng/ml. In selected experiments, purified monocytes were incubated with GM-CSF-containing complete medium for 4 h, in the presence or absence of 10 ng/ml Bortezomib, followed by extensive washing and replating in GM-CSF-containing complete medium for 2-6 days, as indicated, with no further addition of Bortezomib. Following culture, cells were harvested and assayed for their viability by the Trypan Blue assay and processed for cytological and phenotypic evidence of apoptosis, as detailed below.
Differentiation and maturation of DCs
The DCs were differentiated from monocytes as described. 23 Briefly, immature DCs refer to CD1a-expressing cells obtained following culture of purified monocytes for 6 days in the presence of GM-CSF and IL-4. Mature DCs refer to CD83-expressing cells obtained following culture of immature DC for 24-48 h in the presence of lipopolysaccharide. Expression of CD1a and CD83, as well as of the co-stimulatory molecules CD40, CD80 and CD86, was determined by staining with the appropriate FITC-or PE (phycoerythrin)-conjugated MoAbs (all purchased from BD-Pharmingen) or an isotype-matched irrelevant control, followed by acquisition and analysis as described above.
Phenotypic analysis of subpopulations of MNC Sub-populations of MNC were analyzed by flow cytometry before and after culture in the presence or absence of Bortezomib. T lymphocytes were identified as CD3 þ CD4 þ and CD3 þ CD8 þ , B lymphocytes as CD19 þ , and natural killer (NK) cells as CD56 þ . Monocytes were identified as CD14 þ and included both CD16 þ and CD16À subsets. DCs were identified as negative for lineage markers (CD3, CD14, CD16, CD19 and CD56) and HLA-DR þ . For staining, 10 6 MNC were incubated with the appropriate MoAbs (all from BD-Pharmingen) for 15 min at 4 1C, and then, following washing, data acquisition was performed on a FACSCalibur (BD-Pharmingen) by using Cell Quest (BD-Pharmingen) software. Cell percentages were determined following electronic gating of each cell subset by using Cell Quest software.
Detection of apoptosis
Apoptosis was detected on the basis of cytological and phenotypic analysis. For cytological analysis, 10 5 cells were resuspended in 100 ml normal saline and then spun onto slides. Following staining with May Grunwald Giemsa solution, cytospins were examined on a light microscope. Apoptotic cells were defined on the basis of nuclear condensation and fragmentation, cytoplasmic vacuolization and membrane blebbing. Images were visualized using an Olympus BX41 microscope (Olympus Optical Co., Ltd), equipped with an Olympus UPlanFI Â 40/075 numerical aperture objective. Images were captured using an Olympus digital camera Camedia C-3040ZOOM. For phenotypic analysis, apoptotic cells were identified on the basis of surface expression of phosphatydilserine, as revealed by staining with annexin V, by using the Annexin V-FLUOS staining kit (Roche Diagnostics, Penzberg, Germany) according to the manufacturer's instructions. Briefly, cells were incubated for 10 min with a solution containing both annexin V and propidium iodide (Annexin V FLUOS binding solution). Cells were then analyzed on the FACS Calibur using Cell Quest software. Annexin V þ PIÀ events were considered early apoptotic cells, whereas annexin V þ PI þ cells represented late apoptotic cells. Necrotic cells were identified as annexin VÀ PI þ events.
Statistical analysis
Cell percentages as well as percentages of apoptotic cells were compared by means of t-test for paired samples.
Results

Selective depletion of monocytes and DCs following culture of unfractionated MNCs with Bortezomib
To test whether Bortezomib selectively targeted the cells belonging to the monocyte/DC lineage, unfractionated MNCs were incubated for 24 h with various doses of Bortezomib (0.1-100 ng/ml). Percentages of CD4 þ and CD8 þ T lymphocytes, B lymphocytes, NK cells, monocytes (including both CD16 þ and CD16À subsets) and PBDC (identified as lineage-HLA-DR þ ) were identified both before and after in vitro culture. As shown in Figure 1 , the cellular composition did not change following culture for 24 h in control medium. The addition of Bortezomib induced the complete disappearance of CD14 þ monocytes at doses as low as 5 ng/ml (Figures 1a  and b ) (Po0.05 at 5-100 ng/ml). CD14 þ CD16 þ monocytes were similarly depleted (Figure 1a) . By contrast, percentages of T lymphocytes were not affected even at doses as high as 100 ng/ml (Figures 1a and b) . Both B lymphocytes and NK cells were not decreased at doses up to 50 ng/ml Bortezomib, although their percentage appeared to decline upon culture with 100 ng/ml (Figure 1b ) (Po0.05 for both cell subtypes at 100 ng/ml). DC percentages (1 ± 0.2% at baseline) decreased following culture with (o0.01% at X5 ng/ml) and without (0.3 ± 0.1%) Bortezomib, although the loss following exposure to Bortezomib was more pronounced. Thus, incubation of unfractionated MNCs with Bortezomib for Bortezomib induces selective apoptosis of purified monocytes and DCs To confirm that Bortezomib could directly deplete cells belonging to the monocyte/DC lineage in vitro, purified monocytes were incubated in complete medium containing GM-CSF in the presence of increasing doses of Bortezomib (0.1-50 ng/ml). The addition of Bortezomib at X10 ng/ml was associated with decreased recovery of monocytes both at 24 (52±23% in control cultures as compared to 3±1% in Bortezomib cultures, n ¼ 6 experiments) (P ¼ 0.01) and 48 h (31 ± 22% versus 3 ± 1%, n ¼ 5 experiments) (P ¼ 0.03). Recovery of monocytes was not affected by Bortezomib at 0.1 ng/ml, whereas at 1 ng/ml a trend was observed toward a reduced recovery of monocytes both at 24 (31±20%) and 48 h (17±18%) (P ¼ NS). Similar results were observed when monocytes were cultured with GM-CSF and IL-4, to drive their differentiation to DCs. Depletion of monocytes was due to cell death, as suggested by the observation that Bortezomib cultures contained mostly cell 'shadows' as shown in Figures 2b and c. To test whether monocyte death induced by Bortezomib was due to apoptosis, we determined the membrane expression of phosphatydilserine, an early marker of apoptosis, through staining with FITC-conjugated annexin V. As shown in Figure 2a , incubation with Bortezomib for 24 h induced a dose-dependent increase of the percentage of annexin V þ cells, up to 60 ± 25% at 1 ng/ml and 88 ± 6% at 10 ng/ml, consistent with an ED 50 of between 1 and 10 ng/ml, as shown in Figure 2d . Thus, Bortezomib induced massive apoptosis of monocytes within 24 h of culture. Interestingly, monocytes that remained viable on culture with Bortezomib at lower doses (that is, at 0.1 and 1 ng/ml) could still differentiate to CD1a þ immature DC and CD83 þ mature DC, expressing the co-stimulatory molecules CD40, CD80 and CD86 at levels comparable to DC generated in the absence of Bortezomib (not shown).
To confirm that the sensitivity to Bortezomib-induced apoptosis was maintained on differentiation of monocytes to immature and mature DC, monocyte-derived DC were incubated with increasing doses of Bortezomib either before (immature DC) or after culture with lipopolysac- charide for at least 24 h. As shown in Figure 2d , both immature and mature DCs underwent apoptosis on culture with Bortezomib for 24 h, resulting in an ED 50 of 1-10 and 10-50 ng/ml, respectively, as previously described. [12] [13] [14] The induction of apoptosis by Bortezomib was a specific feature of cells belonging to the monocyte/DC lineage, as Bortezomib did not reduce recovery (not shown) or induce apoptosis of purified B and T lymphocytes after 24 h of culture, except at doses 450 ng/ml (Figure 2e) . Similar results were obtained with purified CD34 þ progenitor cells (Figure 2e) . As described previously, induction of T lymphocyte proliferation with PHA or anti-CD3 increased their sensitivity to Bortezomib, resulting in higher percentages of apoptotic cells following their exposure to Bortezomib (data not shown). 8 Thus, incubation with Bortezomib induces the apoptosis of monocytes and monocyte-derived DCs with high selectivity as compared to B and T lymphocytes as well as hematopoietic progenitor cells.
Kinetics of apoptosis induction by Bortezomib
On the basis of pharmacokinetic studies performed in patients treated with current biweekly regimens, plasma
Bortezomib half life appears to be in the range of a few hours, 24 making it unlikely that in vivo circulating cells will be exposed to Bortezomib for as long as 24 h. Therefore, we tested whether monocytes could be induced to undergo apoptosis after a shorter exposure to Bortezomib. Monocytes were incubated with Bortezomib for 4, 8, 12, 16 or 24 h. As shown in Figure 3a , exposure for up to 12 h was not associated with increased apoptosis, whereas the percentage of apoptotic cells increased after 16 and 24 h incubation (41±5% and 83±3%). Therefore, the induction of monocyte apoptosis appears to require 412 h exposure to Bortezomib in vitro.
As the appearance of phosphatydilserine on the cell membrane is a late event in the apoptotic cascade, we hypothesized that short-term (a few hours) incubation with Bortezomib might be sufficient to irreversibly commit monocytes to undergo apoptosis, even after removal of Bortezomib from the culture. To test this hypothesis, monocytes were incubated with or without Bortezomib for 4 h, and then, following extensive washing, recultured in standard conditions. As shown in Figure 3b , monocytes that had been cultured with Bortezomib for 4 h showed increased apoptosis both at 72 h (74±14%) and 144 h (68±30%) (n ¼ 4) as compared to 22-28% in control cultures. Thus, short-term (up to 4 h) incubation with Bortezomib commits monocytes to undergo apoptosis following further culture. It appears, therefore, that in vivo administration of Bortezomib might result in sufficient exposure of circulating monocytes to Bortezomib so as to induce their apoptosis in vivo.
Discussion
This study shows that Bortezomib induces the selective apoptosis of cells belonging to the monocyte/DC lineage in vitro. Monocytes, immature monocyte-derived and mature monocyte-derived DC appear to be equally sensitive to proteasome inhibition by Bortezomib. Apoptosis is determined by short-term (as little as 4 h) exposure to doses of Bortezomib within the range observed in vivo in clinical trials.
The data presented here confirm and extend the results of recent studies showing that Bortezomib induces the apoptosis of DC in vitro. Immature monocyte-derived DC appear to be most sensitive to the effects of Bortezomib. [12] [13] [14] However, the data on the effect of Bortezomib on mature DC are more controversial: although our study shows that mature DC are partially resistant to proteasome inhibition, consistent with a recent study, 13 at least two other studies have shown substantial apoptosis of mature DC upon exposure to Bortezomib. 12, 14 The reasons for this discrepancy is unclear, but it may have to do with the different conditions of DC maturation in the different studies.
However, the effects of proteasome inhibition on the survival of monocytes, the most important precursors of DC in vivo and in vitro, 25 were not reported. Our data show that Bortezomib induces the apoptosis of monocytes as well, which apparently contrasts with previous reports. 14, 26 However, in the former study, lower doses of Bortezomib (up to 3 ng/ml) were used. Moreover, differently than in both reports, in our study monocytes were cultured with GM-CSF to prevent spontaneous apoptosis (36 ± 13%, n ¼ 5, data not shown). 21 As suggested by previous studies, 12, 15 cytokines, such as GM-CSF and IL-4, might increase the sensitivity of monocytes to Bortezomib. Finally, Bortezomib appears to spare other leukocyte subpopulations, such as B and T lymphocytes, suggesting that it may be a selective inhibitor of the function and survival of cells belonging to the monocyte/DC lineage. In addition, Bortezomib may spare CD34 þ hematopoietic progenitors, suggesting its possible use in patients undergoing allogeneic hematopoietic SCT.
The mechanisms underlying the increased sensitivity of monocytes and DC to Bortezomib as compared to lymphoid cells are not known. Bortezomib has been shown to inactivate mcl-1, 27 a bcl-related protein that is thought to be essential to the regulation of monocyte 28 and DC 29 survival. Conversely, there is no evidence that other bclfamily proteins, such as bcl-2, that may play a more important role in lymphocyte survival, are affected by proteasome inhibition. Bortezomib may also interfere with other pathways, such as mitogen-activated protein kinases 6 and nuclear factor-kB, 5 that play a role in the regulation of monocyte and DC survival. However, previous studies and preliminary data from our group (not shown) have shown little or no apoptosis of monocytes following in vitro blockade of PI3K and nuclear factor-kB. 25 However, other cellular factors, such as the rate of spontaneous apoptosis of different cell subsets in vitro, may contribute to the increased sensitivity of monocytes to Bortezomib.
Bortezomib induced the death of monocytes and DCs with an ED 50 comparable to that needed to kill various tumor cells in vitro. 30, 31 Moreover, on the basis of pharmacokinetic data available from clinical trials, Bortezomib concentrations in the range of 1-10 ng/ml are commonly observed in plasma and tissues following in vivo administration. 20 Finally, terminal elimination half-life of Bortezomib has been shown to be as long as 40 h, allowing exposure of tissues to Bortezomib for enough time so as to lead to the induction of apoptosis of target cells.
Therefore, we hypothesize that the administration of Bortezomib might lead to the depletion of monocytes and DC in vivo, which may have important clinical implications, in the context of the recently observed correlation between acute and chronic GVHD and recipient 19 and donor monocyte numbers, respectively. 32 In animal models of GVHD, Bortezomib administration has been shown to prevent GVHD, 9,10 although in neither study were its effects on APC numbers and function tested. In addition, in a recent small study 33 Bortezomib has shown some efficacy in the management of chronic GVHD. However, no data have been reported as yet on monocyte and DC numbers in the peripheral blood or tissues of patients receiving Bortezomib in this as well as other studies. Therefore, further studies are necessary to evaluate whether Bortezomib induces the apoptosis of monocytes in SCT patients and whether this contributes to GVHD prevention.
